Repurposing of anticancer drugs: in vitro and in vivo activities against Schistosoma mansoni

Parasites and Vectors

Volumn 8, Issue 1, 2015, Pages

  Cowan, Noemi ^a,b   Keiser, Jennifer ^a,b  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Drug repurposing; Drug screening; Protein kinase inhibitor; Schistosomiasis

Indexed keywords

AFATINIB; ALBUMIN; ANTINEOPLASTIC AGENT; BOSUTINIB; CABOZANTINIB; CELECOXIB; CHLORMETHINE; CRIZOTINIB; GEFITINIB; IDARUBICIN; PONATINIB; REGORAFENIB; SORAFENIB; SUNITINIB; TAMOXIFEN CITRATE; TRAMETINIB; VANDETANIB; ANTISCHISTOSOMAL AGENT; N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYLPIPERIDIN-4-YL)METHOXY)QUINAZOLIN-4-AMINE; PIPERIDINE DERIVATIVE; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ADULT; ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DETERMINATION; DRUG REPOSITIONING; DRUG STRUCTURE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; IC50; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CANCER; KIDNEY CARCINOMA; LARVAL STAGE; LIVER CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; METASTATIC COLORECTAL CANCER; MOUSE; MYELOID LEUKEMIA; NON SMALL CELL LUNG CANCER; NONHUMAN; PANCREATIC NEUROENDOCRINE TUMOR; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; SINGLE DRUG DOSE; THYROID CANCER; THYROID MEDULLARY CARCINOMA; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; DRUG EFFECTS;

SCHISTOSOMA; SCHISTOSOMA MANSONI; VERMES;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG REPOSITIONING; INHIBITORY CONCENTRATION 50; MICE; PIPERIDINES; PYRIDONES; PYRIMIDINONES; QUINAZOLINES; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; SCHISTOSOMICIDES;

EID: 84938917747     PISSN: None     EISSN: 17563305     Source Type: Journal    
DOI: 10.1186/s13071-015-1023-y     Document Type: Article

References (28)

1. Colley DG, Bustinduy AL, Secor WE, King CH. Human schistosomiasis. Lancet. 2014;384:1094-5.
2. Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2197-223.
3. Pedrique B, Strub-Wourgaft N, Some C, Olliaro P, Trouiller P, Ford N, et al. The drug and vaccine landscape for neglected diseases (2000-11): a systematic assessment. Lancet Glob Health. 2013;1:e371-379.
4. Knopp S, Becker SL, Ingram KJ, Keiser J, Utzinger J. Diagnosis and treatment of schistosomiasis in children in the era of intensified control. Expert Rev Anti Infect Ther. 2013;11:1237-58.
5. Panic G, Duthaler U, Speich B, Keiser J. Repurposing drugs for the treatment and control of helminth infections. Int J Parasitol Drugs Drug Resist. 2014;4:185-200.
6. Dissous C, Grevelding CG. Piggy-backing the concept of cancer drugs for schistosomiasis treatment: a tangible perspective? Trends Parasitol. 2011;27:59-66.
7. Beckmann S, Grevelding CG. Imatinib has a fatal impact on morphology, pairing stability and survival of adult Schistosoma mansoni in vitro. Int J Parasitol. 2010;40:521-6.
8. Doerig C, Grevelding CG. Targeting kinases in Plasmodium and Schistosoma: same goals, different challenges. Biochim Biophys Acta. 2015. doi: 10.1016/j.bbapap.2015.03.002.
9. Ingram-Sieber K, Cowan N, Panic G, Vargas M, Mansour NR, Bickle QD, et al. Orally active antischistosomal early leads identified from the open access malaria box. PLoS Negl Trop Dis. 2014;8:e2610.
10. Cowan N, Dätwyler P, Ernst B, Wang C, Vennerstrom JL, Spangenberg T, et al. Activity of N, N' -diarylurea MMV665852 analogs against Schistosoma mansoni. Antimicrob Agents Chemother. 2015;59:1935-41.
11. Berriman M, Haas BJ, LoVerde PT, Wilson RA, Dillon GP, Cerqueira GC, et al. The genome of the blood fluke Schistosoma mansoni. Nature. 2009;460:352-8.
12. Xiao S-H, Keiser J, Chollet J, Utzinger J, Dong Y, Endriss Y, et al. In vitro and in vivo activities of synthetic trioxolanes against major human schistosome species. Antimicrob Agents Chemother. 2007;51:1440-5.
13. Manneck T, Haggenmüller Y, Keiser J. Morphological effects and tegumental alterations induced by mefloquine on schistosomula and adult flukes of Schistosoma mansoni. Parasitology. 2010;137:85-98.
14. Fasano M, Curry S, Terreno E, Galliano M, Fanali G, Narciso P, et al. The extraordinary ligand binding properties of human serum albumin. IUBMB Life. 2005;57:787-96.
15. European Medicines Agency (EMA): CHMP assessment report for GIOTRIF® (afatinib). [ http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Public-assessment-report/human/002280/WC500152394.pdf ]
16. Gelmedin V, Dissous C, Grevelding CG. Re-positioning protein-kinase inhibitors against schistosomiasis. Future Med Chem. 2015;7:737-52.
17. WHO: Preventive Chemotherapy in Human Helminthiasis: Coordinated Use of Anthelminthic Drugs in Control Interventions: A Manual for Health Professionals and Programme Managers. 2006. [ http://whqlibdoc.who.int/publications/2006/9241547103-eng.pdf ]
18. Calabresi P and Parks RE. Chemotherapy of neoplastic diseases. In: Goodman Gilman A, Goodman LS, Rall TW, Murad F, editors. Goodman and Gilman's. The pharmacological basis of therapeutics, 7th ed. New York: MacMillan; 1985. p. 1240-1307.
19. Lee EF, Fairlie WD. Repurposing apoptosis-inducing cancer drugs to treat schistosomiasis. Future Med Chem. 2015;7:707-11.
20. Beckmann S, Long T, Scheld C, Geyer R, Caffrey CR, Grevelding CG. Serum albumin and α-1 acid glycoprotein impede the killing of Schistosoma mansoni by the tyrosine kinase inhibitor Imatinib. Int J Parasitol Drugs Drug Resist. 2014;4:287-95.
21. AstraZeneca: Highlights of prescribing information for CAPRELSA® (vandetanib) tablets. 2011. [ http://www1.astrazeneca-us.com/pi/vandetanib.pdf ]
22. Center for drug evaluation and research. Food and Drug Administration: Pharmacology review(s), MEKINIST® (trametinib), Reference ID: 3298856. 2013. [ http://www.accessdata.fda.gov/drugsatfda-docs/nda/2013/204114Orig1s000PharmR.pdf ]
23. Center for drug evaluation and research. Food and drug administration: Pharmacology review(s), vandetanib, Reference ID: 2923639. 2011. [ http://www.accessdata.fda.gov/drugsatfda-docs/nda/2011/022405orig1s000pharmr.pdf ]
24. Gilmartin AG, Bleam MR, Groy A, Moss KG, Minthorn EA, Kulkarni SG, et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17:989-1000.
25. Gustafson DL, Bradshaw-Pierce EL, Merz AL, Zirrolli JA. Tissue distribution and metabolism of the tyrosine kinase inhibitor ZD6474 (Zactima) in tumor-bearing nude mice following oral dosing. J Pharmacol Exp Ther. 2006;318:872-80.
26. GlaxoSmithKline: Highlights of prescribing information for MEKINIST® (trametinib) tablets. [ http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/204114s000lbl.pdf ]
27. AstraZeneca: Summary of product characteristics CAPRELSA®. [ http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/002315/WC500123555.pdf ]
28. Katz N, Couto FFB, Araújo N. Imatinib activity on Schistosoma mansoni. Mem Inst Oswaldo Cruz. 2013;108:850-3.